Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance) Abou-Alfa, Ghassan K. , Niedzwieski, Donna , Knox, Jennifer J. ... - ASCO GI - J. Clin. Oncol. - 2016 Abstract - Primary - Primary - GI - CALGB-80802
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - - JAMA Oncol - 2019 Manuscript - Primary - Primary - GI - CALGB-80802
Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8) Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80802
Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver Alberts, S. R. , Donohue, J. H. , Mahoney, M. R. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - GI - NCCTG-N014A
NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary - Preliminary - GI - NCCTG-N044J
Adjuvant mFOLFOX6 +/- Cetuxiumab in KRAS Wild Type Patients With Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147. Alberts, S. R. , Sargent, D. J. , Smyrk, T. C. , Shields, A. F. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - GI - NCCTG-N0147
Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver. Alberts, S. , Mahoney, M. R. , Donohue, J. H. , Roh, M. S. ... - - J. Clin. Oncol. - 2007 Abstract - Primary - Primary - GI - NCCTG-N9945
Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849 Alberts, S. , Soori, G. , Shi, Q. , Wigle, D. , Sticca, R. , Miller, R. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary - Preliminary - GI - N0849
Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Fitch, Tom R. , Kim, George P. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary - Primary - GI - N044J
Gemcitabine and Doxetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Reid, Joel M. , Morlan, Bruce W. , Farr, Gist H. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary - Primary - GI - N0041
Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66 Alberts, Steven R. , Roh, Mark S. , Mahoney, Michelle R. ... - - J Clin Oncol - 2010 Manuscript - Primary - Primary - GI - N9945
Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer Alberts, Steven R. , Sargent, Daniel J. , Nair, Suresh ... - - JAMA - 2012 Manuscript - Primary - Primary - GI - N0147
Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. Alberts, Steven R , Sande, Jonathan R , Foster, Nathan R ... - - J Gastrointest Cancer - 2007 Manuscript - Primary - Primary - GI - NCCTG-N9943
Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. Alberts, Steven R , Suman, Vera J , Pitot, Henry C ... - - J Gastrointest Cancer - 2007 Manuscript - Primary - Primary - GI - NCCTG-964251
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods An, Ming-Wen , Han, Yu , Meyers, Jeffrey P. , Bogaerts, Jan ... - - J. Clin. Oncol - 2015 Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-N9741
Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials An, Ming-Wen , Tang, Jun , Grothey, Axel , Sargent, Daniel J. ... - - Contemp Clin Trials Commun - 2020 Manuscript - Secondary-not-in-original - Primary - GI - A151817 , N0026 , N9741 , NCCTG-N9741
Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) -- Findings from the ACCENT dataset. Andre, T. , Shi, Q. , Yothers, G. , Bot, B. , Haller, D. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - GI - NCCTG-N0441
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials André, Thierry , Meyerhardt, Jeffrey , Iveson, Timothy ... - - Lancet Oncol - 2020 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-80702
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Ashley, Amanda C , Sargent, Daniel J , Alberts, Steven R ... - - Cancer - 2007 Manuscript - Primary - Long-Term-Followup - GI - NCCTG-9741
Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators Bardia, A. , Loprinzi, C. , Grothey, A. , Nelson, G. , Alberts, S. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0148
Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators Bardia, Aditya , Loprinzi, Charles , Grothey, Axel , Nelson, Garth ... - - Semin Oncol - 2010 Manuscript - Secondary-not-in-original - Primary - GI - N0148
New strategies to improve drug development in carcinoid tumors (Alliance A021202) Bergsland, Emily K. , Geyer, Susan M. , Mahoney, Michelle R. ... - NETRF - - 2020 Abstract - No-Endpoint - Trial-Description-Only - GI - A021202
New strategies to improve drug development in carcinoid tumors (Alliance A021202) Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - NETRF - - 2019 Abstract - No-Endpoint - Trial-Description-Only - GI - A021202
Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - ASCO - J Clin Oncol - 2019 Abstract - Primary - Primary - GI - A021202
Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - NANETS - Pancreas - 2019 Abstract - Primary - Primary - GI - A021202
Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581 Bertagnolli, M. M. , Niedzwiecki, D. , Hall, M. , Jewell, S. D. ... - ASCO - J. Clin. Oncol. - 2009 Abstract - Secondary - Primary - GI - C9581
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803 Bertagnolli, Monica M. , Niedzwiecki, Donna , Compton, Carolyn C. ... - - J Clin Oncol - 2009 Manuscript - Secondary - Primary - GI - CALGB-150705 , CALGB-89803
Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803 Bertagnolli, Monica M. , Redston, Mark , Compton, Carolyn C. ... - - J Clin Oncol - 2011 Manuscript - Primary - Primary - GI - C150705 , C89803 , C9581
p27Kip1 in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803 Bertagnolli, Monica M. , Warren, Robert S. , Niedzwiecki, Donna ... - - Clin Cancer Res - 2009 Manuscript - Secondary - Primary - GI - CALGB-150705 , C89803
Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials Blanke, C. D. , Bot, B. M. , Thomas, D. M. , Bleyer, A. , Kohne, C. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original - Comprehensive - GI - NCCTG-N9741
Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials Blanke, Charles D. , Bot, Brian M. , Thomas, David M. ... - - J. Clin. Oncol - 2011 Manuscript - Secondary-not-in-original - Comprehensive - GI - N9741
Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer. Bleiberg, H. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Comprehensive - GI - NCCTG-79-41-51 , NCCTG-83-41-51
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52 Bolton, J. S. , O'Connell, M. J. , Mahoney, M. R. , Farr, G. H. Jr ... - - Clin Colorectal Cancer - 2012 Manuscript - Primary - Primary - GI - NCCTG-924652
Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Bonjer, H Jacob , Hop, Wim C J , Nelson, Heidi , Sargent, Daniel J ... - - Arch Surg - 2007 Manuscript - Secondary-not-in-original - Comprehensive - GI - NCCTG-1515
Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance) Brown, Justin C , Zhang, Sui , Niedzwiecki, Donna , Saltz, Leonard B ... - - JNCI Cancer Spectr - 2018 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-89803
Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance) Brown, Justin C , Zhang, Sui , Ou, Fang-Shu , Venook, Alan P ... - - JNCI Cancer Spectr - 2020 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-80405
What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings Campbell, M. E. , Mandrekar, S. J. , Hillman, S. L. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original - Comprehensive - GI - NCCTG-N0026 , NCCTG-N9741
Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in advanced colorectal cancer (ACRC) - lessons learned from N9741. Campbell, M. , Grothey, A. , Sargent, D. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original - Primary - GI - N9741
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant (NEO) CRT followed by Local Excision (LE) in uT2 Rectal Cancer (RC) Chan, E. , Shi, Q. , Garcia-Aguilar, J. , Wolff, B. G. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2010 Abstract - Secondary - Primary - GI - ACOSOG-Z6041
Association of Family History with Cancer Recurrence and Survival Among Patients with Stage III Colon Cancer Chan, Jennifer A. , Meyerhardt, Jeffrey A. , Niedzwiecki, Donna ... - - JAMA - 2008 Manuscript - Secondary-not-in-original - Primary - GI - C89803
Innovative estimation of survival using log-normal survival modelling on ACCENT database Chapman, J W , O'Callaghan, C J , Hu, N , Ding, K , Yothers, G A ... - - Br. J. Cancer - 2013 Manuscript - No-Endpoint - Primary - GI - N0441
Comparison of innovative estimation of efficacy to standard using the ACCENT database. Chapman, J. W. , O'Callaghan, C. , Hu, N. , Ding, K. , Yothers, G. A. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - GI - NCCTG-N0441
Bayesian Variable Selection with Joint Modeling of Categorical and Survival Outcomes: An Application to Individualizing Chemotherapy Treatment in Advanced Colorectal Cancer Chen, Wei , Ghosh, Debashis , Raghunathan, Trivellore E. ... - - Biometrics - 2009 Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-9741
The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance) Cheng, En , Zhang, Sui , Ou, Fang-Shu , Mullen, Brian , Ng, Kimmie ... - - Cancer Epidemiol. Biomarkers Prev. - 2020 Manuscript - Secondary - Primary - GI - CALGB-89803
Predictive and prognostic value of gender in early stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. Cheung, W. Y. , Shi, Q. , O'Connell, M. , Cassidy, J. , Blanke, C. D. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - GI - NCCTG-N0441
The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database Cheung, Winson Y. , Shi, Qian , O'Connell, Michael , Cassidy, James ... - - Clin Colorectal Cancer - 2013 Manuscript - Secondary - Primary - GI - N0441
Incidence of late recurrence in hormone receptor-positive or negative HER2-positive breast cancer receiving adjuvant trastuzumab: The combined analysis of the NCCTG (Alliance) N9831 and NSABP (NRG) B31 Trials Chumsri, Saranya , Li, Zhou , Serie, Daniel J. ... - SABCS - Cancer Res - 2018 Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N9831 , NSABP B-31
Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials Chumsri, Saranya , Serie, Daniel , Mashadi-Hossein, Afshin ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - N9831
Sentinel Lymph Node Biopsy Accurately Stages the Regional Lymph Nodes for T1-T2 Oral Squamous Cell Carcinomas: Results of a Prospective Multi-Institutional Trial Civantos, Francisco J. , Zitsch, Robert P. , Schuller, David E. ... - - J Clin Oncol - 2010 Manuscript - Primary - Primary - GI - ACOSOG-Z0360
Prognostic value of tumor deposits in stage III colon cancer patients, a post hoc analysis of CALGB/SWOG 80702 phase III study Cohen, Romain , Shi, Qian , Meyers, Jeff , Jin, Zhaohui ... - ASCO GI - J Clin Oncol - 2021 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80702
Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001 Corless, C. L. , Ballman, K. V. , Antonescu, C. , Blanke, C. D. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - GI - ACOSOG-Z9001
Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial Corless, Christopher L. , Ballman, Karla V. , Antonescu, Cristina R. ... - - J. Clin. Oncol - 2014 Manuscript - Secondary - Primary - GI - ACOSOG-Z9001
Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance) Cushman, Stephanie M. , Jiang, Chen , Hatch, Ace J. , Shterev, Ivo ... - - Clin. Cancer Res. - 2015 Manuscript - Secondary - Primary - GI - CALGB-80203
Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC) Das, Rahul K , Furchtgott, Leon , Meyerhardt, Jeffrey A. ... - ESMO - Ann Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identifies heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC) Das, Rahul K , Ou, Fang-Shu , Washburn, Cecilia , Nixon, Andrew B. ... - ESMO GI - Annals of Oncology - 2019 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
Association between 3 year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (REC) in patients receiving cytotoxic adjuvant therapy for colon cancer: Updated findings from the 20,800 patient (Pt) ACCENT dataset De Gramont, A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary - Primary - GI - N0441
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor (GIST): ACOSOG Z9000 (Alliance) intergroup phase 2 trial DeMatteo, Ronald P. , Ballman, Karla V. , Antonescu, Cristina R. ... - - Ann. Surg. - 2013 Manuscript - Primary - Long-Term-Followup - GI - ACOSOG-Z9000
Placebo-Controlled Randomized Trial of Adjuvant Imatinib Mesylate Following the Resection of Localized, Primary Gastrointestinal Stromal Tumor (GIST) DeMatteo, Ronald P. , Ballman, Karla V. , Antonescu, Cristina R. ... - - Lancet - 2009 Manuscript - Primary - Primary - GI - ACOSOG-Z9001
Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000 Dematteo, R. P. , Owzar, K. , Antonescu, C. R. , Maki, R. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary - Primary - GI - ACOSOG-Z9000
Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001 Dematteo, R. , Owzar, K. , Maki, R. , Pisters, P. , Blackstein, M. ... - ASCO - ASCO Annual Meeting - 2007 Abstract - Primary - Primary - GI - ACOSOG-Z9001
Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative Science from CALGB 80802 Dercle, Laurent , Geyer, Susan , Nixon, Andrew , Innocenti, Federico ... - ASCO GI - J Clin Oncol - 2021 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80802
Alliance/CALGB 80802 impact of hepatitis c (HCV) on doxorubicin (D) + sorafenib (S) vs. s in patients (pts) advanced HCC (aHCC) Dika, Imane El , Geyer, Susan M. , Nixon, Andrew ... - ASCO GI - J Clin Oncol - 2021 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80802
A cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE nested in a multicenter trial of multimodal therapy for rectal cancer (Alliance N1048 PROSPECT) Dueck, Amylou C. , Mitchell, S.A. , Rogak, Lauren I. , Ginos, Brenda ... - ISOQOL - Qual Life Res - 2015 Abstract - Secondary - Primary - GI - N1048
Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144 Dy, Grace K. , Hobday, Timothy J. , Nelson, Garth ... - - Clin Colorectal Cancer - 2009 Manuscript - Primary - Primary - GI - N0144
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. Dy, Grace K , Krook, James E , Green, Erin M , Sargent, Daniel J ... - - J. Clin. Oncol. - 2007 Manuscript - Secondary - Primary - GI - N9741
CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer Enzinger, P. C. , Burtness, B. , Hollis, D. R. , Niedzwiecki, D. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - GI - CALGB-80403
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers Enzinger, Peter C. , Burtness, Barbara Ann , Niedzwiecki, Donna ... - - J. Clin. Oncol - 2016 Manuscript - Primary - Primary - GI - CALGB-80403 , ECOG-1206
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance) Fadelu, Temidayo , Zhang, Sui , Niedzwiecki, Donna , Ye, Xing ... - - J. Clin. Oncol - 2018 Manuscript - Secondary - Primary - GI - CALGB-89803
Nut Consumption and Survival in Stage III Colon Cancer Patients: Results from CALGB 89803 (Alliance) Fadelu, Temidayo , Zhang, Sui , Niedzwiecki, Donna , Ye, Xing ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original - Primary - GI - CALGB-89803
Lymphatic Drainage Patterns in Oral Squamous Cell Carcinoma: Findings of the ACOSOG Z0360 (Alliance) Study Farmer, Roger W. , McCall, Linda , Civantos, Francisco J. ... - - Otolaryngol Head Neck Surg - 2015 Manuscript - Secondary - Primary - GI - ACOSOG-Z0360
Five year results from the COST trial testing laparoscopic versus open colectomy for colon cancer Fleshman, J. , Sargent, D. , Green, E. , Anvari, M. , Stryker, S. ... - - EJC Supplement - 2007 Abstract - Primary - Primary - GI - INT-0146
Disease Free Survival and Local Recurrence for Laparoscopic Resection Compared to Open Resection of Stage II-III Rectal Cancer: Follow up Results of the ACOSOG Z6051 Randomized Controlled Trial Fleshman, J , Branda, ME , Sargent, DJ , Boller, AM , George, VV ... - - Ann. Surg. - 2019 Manuscript - Secondary - Primary - GI - ACOSOG-Z6051
Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes Fleshman, James , Branda, Megan , Sargent, Daniel J. ... - - JAMA - 2015 Manuscript - Primary - Primary - GI - ACOSOG-Z6051
Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Fleshman, James , Sargent, Daniel J , Green, Erin , Anvari, Mehran ... - - Ann. Surg. - 2007 Manuscript - Primary - Primary - GI - NCCTG-1515
Body mass index (BMI) and DNA mismatch repair status in colon cancers from patients treated in adjuvant therapy trials. Foster, N. R. , Sinicrope, F. , Yothers, G. , Allegra, C. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - GI - N994C
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of NCCTGs phase III trials N9741 and N9841. Franko, J. , Shi, Q. , Goldman, C. D. , Pockaj, B. A. , Nelson, G. D. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Comprehensive - GI - N9841 , N9741
Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841 Franko, Jan , Shi, Qian , Goldman, Charles D. , Pockaj, Barbara A. ... - - J Clin Oncol - 2012 Manuscript - Secondary-not-in-original - Comprehensive - GI - N9841 , N9741
Model-based prediction of defective DNA mismatch repair using clinicopathological variables in stage II and III colon cancers. French, A. , Sinicrope, F. , Foster, N. , Thibodeau, S. , Sargent, D. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original - Comprehensive - GI - N994C
Prognostic Significance of Defective Mismatch Repair and BRAF-V600E in Patients with Colon Cancer French, Amy J. , Sargent, Daniel J. , Burgart, Lawrence J. ... - - Clin Cancer Res - 2008 Manuscript - Secondary - Primary - GI - NCCTG-98-46-54
Dietary and lifestyle determinants of colon cancer recurrence and survival Fuchs, C. S. , Meyerhardt, J. A. , Ng, K. , Niedzwiecki, D. ... - NCI TSM - - 2008 Abstract - Secondary - Long-Term-Followup - GI - C89803
KRAS mutation, cancer recurrence and patient survival in stage III colon cancer: Findings from CALGB 89803 Fuchs, C. S. , Ogino, S. , Meyerhardt, J. A. , Irahara, N. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary - Primary - GI - C89803
Postoperative adjuvant chemoradiation for gastric or gastroesophageal (GE) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): Results from Intergroup trial CALGB 80101 Fuchs, C. S. , Tepper, J. E. , Niedzwiecki, D. , Hollis, D. R. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Primary - Primary - GI - CALGB-80101
Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741 Fuchs, Charles S. , Goldberg, Richard M. , Sargent, Daniel J. ... - - Clin Cancer Res - 2008 Manuscript - Secondary - Primary - GI - N9741
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance) Fuchs, Charles S. , Niedzwiecki, Donna , Mamon, Harvey J. ... - - J. Clin. Oncol - 2017 Manuscript - Primary - Primary - GI - CALGB-80101
Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance) Fuchs, M. A. , Yuan, C. , Sato, K. , Niedzwiecki, D. , Ye, X. ... - - Ann. Oncol - 2017 Manuscript - Secondary - Primary - GI - CALGB-89803
Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance) Fuchs, Michael A. , Sato, Kaori , Niedzwiecki, Donna , Ye, Xing ... - - PLoS ONE - 2014 Manuscript - Secondary - Primary - GI - CALGB-89803
Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary tumor side. Furchtgott, Leon , Swanson, David , Hayete, Boris , Khalil, Iya ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) and local excision (LE) for uT2uN0 rectal cancer (RC): results of the ACOSOG Z6041 trial Garcia-Aguilar, J. , Shi, Q. , Thomas, C. R., Jr , Chan, E. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - GI - ACOSOG-Z6041
Organ preservation for clinical t2n0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision: results of a multicenter phase 2 study Garcia-Aguilar, Julio , Renfro, Lindsay A. , Chow, Oliver S. ... - - Lancet Oncol. - 2015 Manuscript - Primary - Primary - GI - ACOSOG-Z6041
A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial Garcia-Aguilar, Julio , Shi, Qian , Thomas, Charles R. , Chan, Emily ... - - Ann. Surg. Oncol. - 2012 Manuscript - Primary - Preliminary - GI - ACOSOG-Z6041
RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer Gbenedio, Oghenekevwe M. , Bonnans, Caroline , Grun, Delphine ... - - JCI Insight - 2019 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-80203
Discordance between central vs. local response assessments in neuroendocrine tumor (NET) patients enrolled in A021202. Geyer, Susan M. , Mahoney, Michelle R. , Asmis, Timothy R. ... - ASCO GI - J Clin Oncol - 2021 Abstract - Secondary - Primary - GI - A021202
Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!). Gill, S. , Loprinzi, C. , Kennecke, H. , Grothey, A. , Nelson, G. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original - Comprehensive - GI - N0148
Prognostic Web-based Models for Stage II and III Colon Cancer: a Population and Clinical Trials-based Validation of Numeracy and Adjuvant! Online Gill, Sharlene , Loprinzi, Charles , Kennecke, Hagen , Grothey, Axel ... - - Cancer - 2011 Manuscript - Secondary-not-in-original - Meta-Analysis - GI - NCCTG-89-46-51 , NCCTG-914653
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Goel, Ajay , Nagasaka, Takeshi , Arnold, Christian N , Inoue, Toru ... - - Gastroenterology - 2007 Manuscript - Secondary - Primary - GI - CALGB-9865
A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in 9 first line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC). Goldberg, R. M. , Kohne, C. H. , Seymour, M. T. , De Gramont, A. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original - Comprehensive - GI - N0545 , N9741
Adjuvant mFOLFOX6 +/- Cetuximab in Patients With KRAS Mutant Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147. Goldberg, R. , Sargent, D. , Thibodeau, S. , Mahoney, M. , Shields, A. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - GI - N0147
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. Goldberg, Richard M , Sargent, Daniel J , Morton, Roscoe F ... - - J. Clin. Oncol. - 2004 Manuscript - Primary - Primary - GI - NCCTG-N9741
Variability of Pelvic MRI Performance in a Prospective Multicenter Rectal Cancer Trial NCCTG N1048 (Alliance) Gollub, Marc J. , Shi, Qian , Nougaret, Stephanie ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - N1048
Survival Outcomes from CALGB 80803 (Alliance): A Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy for Esophageal Cancer Goodman, Karyn A. , Hall, Nathan , Bekaii-Saab, Tanios , Ou, Fang-Shu ... - ASCO - J. Clin. Oncol. - 2018 Abstract - Secondary - Primary - GI - CALGB-80803
Initial results of CALGB 80803: A randomized phase II trial of pet scan-directed combined modality therapy for esophageal cancer (Alliance) Goodman, Karyn A. , Niedzwiecki, Donna , Hall, Nathan ... - ASCO GI - J Clin Oncol - 2017 Abstract - Primary - Preliminary - GI - CALGB-80803
Local excision of distal rectal cancer: An update of Cancer and Leukemia Group B 8984 Greenberg, J. A. , Shibata, D. , Herndon, J. E. 2nd ... - - Am Soc Colon Rectal Surg - 2008 Abstract - Primary - Long-Term-Followup - GI - C8984
Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. Greenberg, Jacob A , Shibata, David , Herndon, James E ... - - Dis. Colon Rectum - 2008 Manuscript - Primary - Long-Term-Followup - GI - C8984
New lesions vs. growth of existing disease: does it impact prognosis? Grothey, A. , Heun, J. M. , Branda, M. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Primary - GI - N9741
Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): results of the phase II North Central Cancer Treatment Group Study N054C Grothey, A. , Lafky, J. M. , Morlan, B. W. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - GI - N054C
Baseline quality of life (QOL) is a strong and performance status (PS)-independent prognostic factor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC) Grothey, A. , Sargent, D. J. , Szydlo, W. , Zhao, X. , Campbell, M. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Secondary - Primary - GI - NCCTG-N9741
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer Grothey, A. , Sobrero, A.F. , Shields, A.F. , Yoshino, T. , Paul, J. ... - - N. Engl. J. Med. - 2018 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-80702
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. Grothey, Axel , Hedrick, Eric E , Mass, Robert D , Sarkar, Somnath ... - - J. Clin. Oncol. - 2008 Manuscript - Secondary-not-in-original - Primary - GI - N9741
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration Grothey, Axel , Sobrero, Alberto F. , Meyerhardt, Jeffrey A. ... - ESMO - Annals of Oncology - 2017 Abstract - Secondary-not-in-original - Comprehensive - GI - CALGB-80702
Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB 80405 (Alliance) Guercio, Brendan J. , Venook, Alan P. , Niedzwiecki, Donna ... - ASCO GI - J Clin Oncol - 2017 Abstract - Secondary - Preliminary - GI - CALGB-80405
Associations of Insulin-Like Growth Factor Binding Proteins and Adiponectin with Disease Progression and Mortality in Metastatic Colorectal Cancer: Results from CALGB/SWOG 80405 (Alliance) Guercio, Brendan J. , Venook, Alan P. , Zhang, Sui , Ou, Fang-Shu ... - ASCO - J. Clin. Oncol. - 2019 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance) Guercio, Brendan J. , Zhang, Sui , Niedzwiecki, Donna , Li, Yanping ... - - PLoS ONE - 2018 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-89803
Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer (Alliance) Guercio, Brendan J. , Zhang, Sui , Venook, Alan P. , Ou, Fang-Shu ... - AACR - Cancer Res - 2019 Abstract - Secondary - Primary - GI - CALGB-80405
Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Guercio, Brendan J , Zhang, Sui , Ou, Fang-Shu , Venook, Alan P ... - - J. Clin. Oncol. - 2019 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-80405
IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405 Guercio, Brendan J , Zhang, Sui , Ou, Fang-Shu , Venook, Alan P ... - - JNCI Cancer Spectr - 2020 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-80405
Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405 Guercio, Brendan J , Zhang, Sui , Venook, Alan P , Ou, Fang-Shu ... - - JNCI Cancer Spectr - 2020 Manuscript - Secondary - Primary - GI - CALGB-80405
Phase II study of oxaliplatin, 5-FU and RT followed by gemcitabine in patients with unresectable pancreatic cancer. Haddock, M. , Kim, G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary - Primary - GI - NCCTG-N0349
Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. Haddock, Michael G , Swaminathan, Revathi , Foster, Nathan R ... - - J. Clin. Oncol. - 2007 Manuscript - Primary - Primary - GI - N9942
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance) Halfdanarson, Thorvardur R. , Foster, Nathan R. , Kim, George P. ... - - Oncologist - 2019 Manuscript - Primary - Primary - GI - N064B
A comparison of two methodologies to quantify Thymidylate synthase for predicting survival in patients with colorectal cancer treated on CALGB 89803 Hasson, R. M. , Niedzwiecki, D. ... - AACR - Cancer Res. - 2012 Abstract - Secondary - Primary - GI - CALGB-89803
On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance) Hatch, Ace J. , Ou, Fang-Shu , Zemla, Tyler , Liu , Star, Mark D. ... - ASCO GI - J. Clin. Oncol - 2019 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance). Hatch, Ace Joseph , Pang, Herbert , Starr, Mark D. , Brady, John C. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80203
Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405 Heinemann, Volker , Niedzwiecki, Donna , Pearline, Rachel ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741 Heun, James M. , Grothey, Axel , Branda, Megan E. ... - - Oncologist - 2011 Manuscript - Secondary - Primary - GI - NCCTG-N9741
Questionable value of attribution when interpreting adverse event data: A joint evaluation by North Central Cancer Treatment Group (NCCTG) and American College of Surgeons Oncology Group (ACOSOG). Hillman, SL , Sargent, DJ , Bot, BM , RP, DeMatteo , Perez, EA ... - ASCO - J Clin Oncol - 2007 Abstract - Secondary-not-in-original - Primary - GI - ACOSOG-Z9001
Evaluation of the Optimal Number of Lesions Needed for Tumor Evaluation Using the Response Evaluation Criteria in Solid Tumors: A North Central Cancer Treatment Group Investigation Hillman, Shauna L. , An, Ming-Wen , O'Connell, Michael J. ... - - J Clin Oncol - 2009 Manuscript - Secondary-not-in-original - Comprehensive - GI - N9741
Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147 Huang, J. , Sargent, D. J. , Mahoney, M. R. , Shields, A. F. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - GI - N0147
Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147 Huang, J. , Sargent, D. J. , Mahoney, M. R. , Thibodeau, S. N. ... - ASCO GI - J Cin Oncol 29, No 4_suppl (February - 2011 Abstract - Primary - Primary - GI - N0147
Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147 Huang, Jocelin , Nair, Suresh G. , Mahoney, Michelle R. ... - - Clin Colorectal Cancer - 2014 Manuscript - Primary - Long-Term-Followup - GI - NCCTG-N0147
Phase I evaluation of sorafenib (SOR) & bevacizumab (BEV) in first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group Trial N0745 Hubbard, J. , Alberts, S. , Loui, W. , Mahoney, M. , Roberts, L. ... - - J. Clin. Oncol. - 2011 Abstract - Primary - Primary - GI - N0745
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group trial N0745 (Alliance) Hubbard, Joleen M. , Mahoney, Michelle R. , Loui, William S. ... - - Target Oncol - 2017 Manuscript - Primary - Primary - GI - N0745
Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set Hubbard, Joleen , Thomas, David M. , Yothers, Greg , Green, Erin ... - - J. Clin. Oncol - 2012 Manuscript - Secondary - Comprehensive - GI - ACCENT , CALGB-89803
Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance) Hurwitz, H. , Cushman, S. , Jiang, C. , Shterev, I. , Mahoney, M. R. ... - - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80203
Causal modeling of CALGB 80405 (Alliance) identifies network drivers of metastatic colorectal cancer (CRC) Innocenti, Federico , Lenz, Heinz-Josef , Meyerhardt, Jeffrey ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
The vitamin D receptor gene is a determinant of survival in advanced pancreatic cancer patients Innocenti, Federico , Owzar, Kouros , Jiang, Chen , Seiser, Eric ... - ECC - - 2015 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80303
Next-generation sequencing (NGS) in patients (pts) with metastatic colorectal cancer (mCRC): novel mutated genes and differential response to therapy (Alliance) Innocenti, Federico , Rashid, Naim , Mu, Wancen , Ou, Fang-Shu ... - ESMO - Annals of Oncology - 2019 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803 Jackson, N. A. , Fuchs, C. S. , Niedzwiecki, D. , Hollis, D. R. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary - Primary - GI - C89803
Elderly patients with metastatic esophageal/gastric cancer: a pooled analysis of age-based outcomes from 8 consecutive North Central Cancer Treatment Group (NCCTG) therapeutic trials Jatoi, A. , Foster, N. R. , Egner, J. , Burch, P. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - GI - N064C
Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)1 Jatoi, Aminah , Dakhil, Shaker R. , Foster, Nathan R. , Ma, Cynthia ... - - J Thorac Oncol - 2008 Manuscript - Primary - Primary - GI - N044B
Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147 Jatoi, Aminah , Green, Erin M. , Rowland, Kendrith M. Jr. ... - - Oncology - 2009 Manuscript - Secondary - Primary - GI - N0147
Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Jatoi, Aminah , Martenson, James A , Foster, Nathan R ... - - Am. J. Clin. Oncol. - 2007 Manuscript - Primary - Primary - GI - N0044
Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma. Jatoi, Aminah , Nguyen, Phuong L , Foster, Nathan , Sun, David ... - - J Support Oncol - 2007 Manuscript - Secondary - Primary - GI - N0242
Phase II Study of Preoperative Pemetrexed, Carboplatin, and Radiation Followed by Surgery for Locally Advanced Esophageal Cancer and Gastroesophageal Junction Tumors Jatoi, Aminah , Soori, Gamini , Foster, Nathan R. , Hiatt, Bradley ... - - J Thorac Oncol - 2010 Manuscript - Primary - Primary - GI - N044E
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib Joensuu, Heikki , Eriksson, Mikael , Hall, Kirsten Sundby ... - - Cancer - 2014 Manuscript - Secondary-not-in-original - Primary - GI - ACOSOG-Z9001
Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E Katipamula, Rajini , Jatoi, Aminah , Foster, Nathan R. ... - - Clin Med Oncol - 2008 Manuscript - Secondary - Preliminary - GI - N044E
Standardization and documentation of surgical and pathologic variables in a multi-institutional trial of adjuvant therapy for pancreatic cancer: Results from ACOSOG Z5031 Katz, M. H. , Merchant, N. B. , Brower, S. , Campbell, M. ... - SSO - SSO Annual Meeting - 2010 Abstract - Secondary-not-in-original - Primary - GI - ACOSOG-Z5031
Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial Katz, Matthew H. G. , Merchant, Nipun B. , Brower, Steven ... - - Ann. Surg. Oncol. - 2011 Manuscript - Secondary-not-in-original - Primary - GI - ACOSOG-Z05031
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas Katz, Matthew H. G. , Ou, Fang-Shu , Herman, Joseph M. ... - - BMC Cancer - 2017 Manuscript - No-Endpoint - Trial-Description-Only - GI - A021501
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Katz, Matthew H. G. , Shi, Qian , Ahmad, Syed A. , Herman, Joseph M. ... - - JAMA Surg - 2016 Manuscript - Primary - Primary - GI - A021101
Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101. Katz, Matthew H.G. , Shi, Qian , Ahmad, Syed , Herman, Joseph ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary - Primary - GI - A021101
Borderline resectable pancreatic cancer: Need for Standardization and Methods for Optimal Clinical Trial Design Katz, Matthew HG , Marsh, Robert , Herman, Joseph M. , Shi, Qian ... - - Ann. Surg. Oncol. - 2013 Manuscript - No-Endpoint - Comprehensive - GI - A021101
Alliance for clinical trials in oncology trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas Katz, Matthew , Herman, Joseph M. , Ou, Fang-Shu , Marsh, Robert ... - ASCO - J. Clin. Oncol. - 2017 Abstract - No-Endpoint - Trial-Description-Only - GI - A021501
Alliance trial A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas Katz, Matthew , Shi, Qian , Meyers, Jeff , Herman, Joseph M. ... - ASCO GI - J Clin Oncol - 2021 Abstract - Primary - Primary - GI - A021501
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). Kemeny, Nancy E , Niedzwiecki, Donna , Hollis, Donna R ... - - J. Clin. Oncol. - 2006 Manuscript - Primary - Primary - GI - CALGB-9481
North Central Cancer Treatment Group phase II study of panitumumab (Pmab), chemotherapy, and external beam radiation (Chemo-RT) in patients with locally advanced (LA) pancreatic cancer Kim, G. P. , Foster, N. R. , Haddock, M. G. , Dakhil, S. R. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - GI - N064A
Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma Kim, G. P. , Foster, N. R. , Salim, M. , Flynn, P. J. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Primary - Primary - GI - N064B
Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU) and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer Kim, G. P. , Haddock, M. G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary - Long-Term-Followup - GI - NCCTG-N0349
Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemicitabine (GEM) in patients with unresectable pancreatic cancer Kim, G. P. , Haddock, M. , Foster, N. R. , Bollinger, J. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary - Long-Term-Followup - GI - N0349
Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC) Kim, G. P. , Marsoni, S. , Monges, G. , Allegra, C. J. ... - - J. Clin. Oncol. - 2010 Abstract -
